CureVac Acquisition Enters Final Phase as BioNTech Integration Accelerates

The new trading year has begun on a positive note for CureVac, with its shares posting significant gains. This upward movement reflects the market’s anticipation of the final stages of its acquisition by fellow German biotech firm BioNTech. Investor focus has now shifted to the technical completion of the deal and the timeline for CureVac’s eventual disappearance as an independent listed entity.

• Share Movement: Shares advanced approximately 4.5% to €3.78.
• Majority Stake: BioNTech already controls a commanding 81.74% of CureVac’s equity.
• Formal Completion: The transaction is expected to be formally finalized in January 2026.
• Management Shift: A key executive departure signals deepening integration efforts.

Operational Changes Highlight Progress

The ongoing integration is becoming evident through personnel changes. A significant development is the departure of Dr. Sarah Fakih, a key CureVac leader who oversaw corporate communications during its recent restructuring phase. She is joining Evotec SE in the role of Executive Vice President. The exit of such a central figure underscores how far the merger has progressed and points to a trend of former CureVac executives moving to other life sciences companies.

The Path to Consolidation

This acquisition marks the conclusion of CureVac’s chapter as a standalone mRNA technology provider. Once a direct competitor to BioNTech in developing mRNA-based vaccines, CureVac faced strategic challenges. Following a search for a robust partner to commercialize its pipeline in oncology and infectious diseases, the consolidation scenario prevailed.

The deal follows a classic market pattern: the target company’s share price converges toward the offer price as the transaction advances. Today’s gain of over 4% indicates investor confidence that the remaining technical conditions for closure will be met smoothly this month. Restructuring efforts in 2024 and 2025, which CureVac states reduced operational costs by more than 30%, have facilitated this integration process for BioNTech.

Should investors sell immediately? Or is it worth buying CureVac?

Transaction Nears Its Conclusion

The current share price movement represents the final act in a broader consolidation within Germany’s biotechnology sector. The takeover of CureVac N.V. by BioNTech is scheduled for formal completion this month, following the expiration of the subsequent acceptance period on December 18, 2025.

The critical minimum acceptance threshold of 80% was surpassed on December 3, 2025, when BioNTech secured its 81.74% stake. Trading around €3.784, the current price aligns closely with final deal expectations, driven largely by arbitrage traders and institutional investors adjusting their positions ahead of a potential delisting or full absorption.

Outlook: Technical Execution in Focus

Throughout January, CureVac’s share price is likely to remain tightly correlated with the formal steps of the acquisition. With the decisive ownership threshold already exceeded, attention now turns to the possibility of a squeeze-out for remaining minority shareholders and a subsequent delisting from the stock exchange.

Operational updates from CureVac itself have become largely irrelevant for valuation, as the company’s independent market presence has effectively ended. The primary driver remains the share price’s proximity to the takeover valuation. The current level near €3.78 confirms market expectations that the deal will be finalized as planned.